TLK2 and breast cancer: Copy-number data from TCGA show that TLK2 is amplified in about ∼9% of all breast cancers (Fig. 1c), and such events are more frequent in ER-positive than negative breast cancers (10.5 versus 2.9%) (Supplementary Fig. 1b).